Christine J. Pak

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader et al. · Journal of Clinical Oncology · 2018 · 367 citations · Full text

Life Sciences, Immunology, Oncology +17

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

Margaretha G.M. Roemer, Ranjana H. Advani, Robert Redd et al. · Cancer Immunology Research · 2016 · 191 citations · Full text

Medicine, Oncology, Pathology +17

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Alex F. Herrera, Matthew Mei, Lawrence K. Low et al. · Journal of Clinical Oncology · 2016 · 187 citations · Full text

Medicine, Oncology, Hematologic Oncology +13

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao et al. · Cancer Immunology Research · 2016 · 166 citations · Full text

Life Sciences, Immunology, Oncology +17

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva

Brooke E. Howitt, Heather H. Sun, Margaretha G.M. Roemer et al. · JAMA Oncology · 2016 · 139 citations · Full text

Medicine, Oncology, Pathology +17